The first Elsevier issue of NeuroRx® will appear in January 2006. Alan I. Faden, M.D., Professor of Neuroscience at Georgetown University Medical Center, will continue to serve as Editor-in-Chief. "Partnering with Elsevier will help us continue to expand the reach of NeuroRx®, supporting our mission of bridging the gap between basic neuroscience research and the development of effective new treatments for neurological diseases," comments Dr. Faden.
NeuroRx® is a unique publication providing critical reviews on selected topics in therapy of neurological disorders. Each quarterly issue focuses on a single topic, with internationally recognized authorities sharing their in-depth understanding. NeuroRx® offers a multidisciplinary perspective on high-profile topics in neurotherapeutics, taking in not just the scientific issues but also their social and ethical ramifications.
The information provided by NeuroRx® is equally valuable to neuroscientists performing basic research and clinicians working in neurology, neurosurgery, psychiatry, and rehabilitation medicine. Scheduled topics for the 2006 issues of NeuroRx® are Neuropsychiatry; Pediatric Neurotherapeutics; Neurorehabilitation and Neurorestoration; and Proteomics, Genomics, Metabolomics. Dr. Faden adds, "These are among the critical topics at the frontiers of translational neuroscience, with the potential to lead to new treatments for important diseases of the brain and nervous system."
Members of ASENT will continue to receive the print edition of NeuroRx®. Members and subscribers will be able to access the entire contents of each issue online at the journal website, www.neurorx.org. Other online features will include a comprehensive search engine, allowing users to search NeuroRx® alone, or to include hundreds of other Elsevier journals and MEDLINE in a single query; options to sign up for e-mail alerts; and embedded links to valuable content, such as the Mosby Drug Consult database. NeuroRx® will also be accessible through Elsevier's institutional subscription service, ScienceDirect (www.sciencedirect.com).
Another key upgrade will be the ability for contributors to submit manuscripts electronically via the Elsevier Editorial System (http://authors.elsevier.com/), streamlining the peer review and editorial process.
"We think NeuroRx® will provide a valuable new addition to Elsevier's line of leading Neurology and Psychiatry journals and books," comments Jane Grochowski, who will serve as Publisher of NeuroRx® for Elsevier. "We look forward to working with our partners at ASENT in producing this publication, with its unique focus on neurotherapeutics from the research lab to the doctor's office."
The purpose of the American Society for Experimental NeuroTherapeutics is to provide a forum for broadly defined interest areas of academia, government, industry and advocacy concerned with the field of neurotherapeutics; to promote dialogue, understanding and cooperation among the interested groups; to develop information and seek consensus on matters germane to the organization's mission; and to organize education and training for healthcare practitioners, biomedical scientists and officials participating in the neurotherapeutics field. Visit the Society's website at www.asent.org.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in 77 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.